Clinical summary of myeloid malignancy cases
| Cohort . | TP53 . | CBF . | |
|---|---|---|---|
| Diagnosis . | AML, n = 29 . | MDS, n = 13 . | AML, n = 18 . |
| Sex | |||
| Male | 66% (19) | 31% (4) | 56% (10) |
| Female | 34% (10) | 69% (9) | 44% (8) |
| Age, y, mean (range) | 65.7 (26-81) | 61.3 (41-85) | 45.5 (20-76) |
| Ethnicity | |||
| Caucasian | 97% (28) | 100% (13) | 100% (18) |
| African American | 3% (1) | ||
| WBC, mean (103 cells per μL) | 9.3 | 5.0 | 34.0 |
| BM blast %, mean | 54% | 7% | 56% |
| PB blast %, mean | 14% | 2% | 39% |
| Subtype | |||
| M0 | 17% (5) | ||
| M1 | 14% (4) | 11% (2) | |
| M2 | 17% (5) | 33% (6) | |
| M4 | 10% (3) | 50% (9) | |
| M5 | 6% (1) | ||
| M6 | 10% (3) | ||
| M7 | 3% (1) | ||
| MRC | 14% (4) | ||
| Not categorized | 14% (4) | ||
| Excess blasts | 77% (10) | ||
| Multilineage dysplasia | 10% (3) | ||
| Therapy related | 3% (1) | 38% (5) | |
| Secondary to MDS | 10% (3) | ||
| Cytogenetics | |||
| Complex | 90% (26) | 100% (13) | |
| inv(3) | 3% (1) | ||
| del(Y) | 3% (1) | ||
| inv(16) | 67% (12) | ||
| t(8;21) | 28% (5) | ||
| Incomplete | 3% (1) | 6% (1) | |
| Previous treatment | |||
| None | 100% (29) | 77% (10) | 100% (18) |
| Hypomethylating agent | 15% (2) | ||
| Lenolidomide | 8% (1) | ||
| TP53status | |||
| Concordant: multihit | 93% (27) | 69% (9) | |
| Discordant: monoallelic → multihit | 7% (2) | 23% (3) | |
| Ambiguous → monoallelic | 8% (1) | ||
| Cohort . | TP53 . | CBF . | |
|---|---|---|---|
| Diagnosis . | AML, n = 29 . | MDS, n = 13 . | AML, n = 18 . |
| Sex | |||
| Male | 66% (19) | 31% (4) | 56% (10) |
| Female | 34% (10) | 69% (9) | 44% (8) |
| Age, y, mean (range) | 65.7 (26-81) | 61.3 (41-85) | 45.5 (20-76) |
| Ethnicity | |||
| Caucasian | 97% (28) | 100% (13) | 100% (18) |
| African American | 3% (1) | ||
| WBC, mean (103 cells per μL) | 9.3 | 5.0 | 34.0 |
| BM blast %, mean | 54% | 7% | 56% |
| PB blast %, mean | 14% | 2% | 39% |
| Subtype | |||
| M0 | 17% (5) | ||
| M1 | 14% (4) | 11% (2) | |
| M2 | 17% (5) | 33% (6) | |
| M4 | 10% (3) | 50% (9) | |
| M5 | 6% (1) | ||
| M6 | 10% (3) | ||
| M7 | 3% (1) | ||
| MRC | 14% (4) | ||
| Not categorized | 14% (4) | ||
| Excess blasts | 77% (10) | ||
| Multilineage dysplasia | 10% (3) | ||
| Therapy related | 3% (1) | 38% (5) | |
| Secondary to MDS | 10% (3) | ||
| Cytogenetics | |||
| Complex | 90% (26) | 100% (13) | |
| inv(3) | 3% (1) | ||
| del(Y) | 3% (1) | ||
| inv(16) | 67% (12) | ||
| t(8;21) | 28% (5) | ||
| Incomplete | 3% (1) | 6% (1) | |
| Previous treatment | |||
| None | 100% (29) | 77% (10) | 100% (18) |
| Hypomethylating agent | 15% (2) | ||
| Lenolidomide | 8% (1) | ||
| TP53status | |||
| Concordant: multihit | 93% (27) | 69% (9) | |
| Discordant: monoallelic → multihit | 7% (2) | 23% (3) | |
| Ambiguous → monoallelic | 8% (1) | ||
BM, bone marrow; MRC, myelodysplastic-related changes; PB, peripheral blood; WBC, white blood cell count.